1/44
Looks like no tags are added yet.
RC is a 59-year-old male with a BMI of 34 kg/m² who presents for diabetes management. His A1c today is 9.4%. Past medical history includes type 2 diabetes mellitus (diagnosed 8 years ago), myocardial infarction 2 years ago, metabolic-associated steatotic liver disease (MASLD), and bladder cancer in remission. He is currently on metformin 1000 mg BID, lisinopril 20 mg daily, and atorvastatin 40 mg daily. He struggles with weight loss and states, “I’m tired of feeling hungry all the time.” Which of the following is the most appropriate next step in therapy?
A. Add pioglitazone
B. Add Ozempic (semaglutide)
C. Add glyburide
D. Switch to insulin detemir
Answer: B. Add Ozempic (semaglutide)
Rationale:
GLP-1 agonists like semaglutide help with glycemic control and weight loss, making it ideal in obese patients.
Semaglutide has cardiovascular benefits, important post-MI.
It does not worsen MASLD and has a favorable hepatic profile.
Pioglitazone is contraindicated with bladder cancer history.
Glyburide increases risk of hypoglycemia and weight gain.
Insulin may be considered later, but starting with GLP-1 is appropriate in this case due to patient preference and comorbidities.
A 68-year-old male with newly diagnosed type 2 diabetes is started on sitagliptin (Januvia) due to his preference for oral medications and a fear of hypoglycemia. Which of the following best explains the mechanism of action and safety profile of this drug?
A. Sitagliptin enhances insulin sensitivity and directly stimulates beta cells to release insulin, increasing hypoglycemia risk.
B. Sitagliptin increases GLP-1 levels by inhibiting DPP-4, resulting in glucose-dependent insulin release with a low risk of hypoglycemia.
C. Sitagliptin acts on the PPAR-γ receptor to reduce insulin resistance and promotes fat redistribution.
D. Sitagliptin suppresses hepatic gluconeogenesis and decreases glucose absorption in the GI tract.
Answer: B. Sitagliptin increases GLP-1 levels by inhibiting DPP-4, resulting in glucose-dependent insulin release with a low risk of hypoglycemia.
Rationale:
Sitagliptin is a DPP-4 inhibitor → inhibits breakdown of incretin hormones (like GLP-1 and GIP)
This leads to glucose-dependent insulin secretion and decreased glucagon release
Because the action is glucose-dependent, the risk of hypoglycemia is low when used alone (not combined with insulin or sulfonylureas)
MJ is a 72-year-old female with a history of type 2 diabetes mellitus, chronic kidney disease (stage 3b), diabetic gastroparesis, and hyperlipidemia. Her current medications include metformin 1000 mg BID, atorvastatin 20 mg daily, and ondansetron PRN. At today’s visit, her lab results show:
Serum Creatinine: 2.1 mg/dL
CrCl: 30 mL/min
A1c: 8.3%
LDL: 92 mg/dL
Which of the following is the most appropriate recommendation?
A. Continue all current medications
B. Increase metformin dose to 1500 mg BID
C. Discontinue metformin due to renal function
D. Switch atorvastatin to simvastatin
Answer: C. Discontinue metformin due to renal function
Rationale:
Metformin is contraindicated when CrCl < 30 mL/min due to the risk of lactic acidosis
Gastroparesis also increases risk of GI side effects with metformin
No changes are needed to atorvastatin at this time
Increasing the dose would be unsafe given renal status
A 56-year-old male presents to the clinic complaining of increased fatigue, excessive thirst, blurry vision, and frequent urination over the past 2 weeks. His only known past medical history is hypertension, controlled with lisinopril. A random blood glucose in clinic is 287 mg/dL. Which of the following best explains his current symptoms?
A. Onset of a urinary tract infection
B. Symptomatic hypoglycemia
C. Hyperglycemia due to insulin resistance
D. Adverse effects of lisinopril
Answer: C. Hyperglycemia due to insulin resistance
Rationale:
Classic symptoms of hyperglycemia include:
Polydipsia (↑ thirst)
Polyuria (↑ urination)
Blurred vision
Fatigue
A random glucose >200 mg/dL with symptoms = diagnostic of diabetes
These symptoms are due to osmotic diuresis and cellular energy deficits from high blood glucose
Hypoglycemia causes the opposite (shakiness, sweating, confusion)
LK is a 60-year-old female with a 10-year history of poorly controlled type 2 diabetes. Her A1c is currently 9.1%, BMI is 36 kg/m², and she has a history of myocardial infarction 3 years ago. She denies any history of medullary thyroid carcinoma (MTC) or pancreatitis. Her current medications include metformin 1000 mg BID, lisinopril 10 mg daily, and rosuvastatin 20 mg daily. Which of the following is the most appropriate next step?
A. Add glyburide
B. Add Victoza (liraglutide)
C. Switch metformin to pioglitazone
D. Add empagliflozin
Answer: B. Add Victoza (liraglutide)
Rationale:
Liraglutide is a GLP-1 receptor agonist with cardiovascular benefit — shown to reduce MACE (major adverse cardiac events) in patients with ASCVD
Also promotes weight loss — great for a patient with high BMI
It’s safe to use as long as there’s no history of MTC or pancreatitis
Glyburide → risk of hypoglycemia and weight gain
Pioglitazone → not preferred in patients with cardiac history
Empagliflozin is also good for CV risk but not the best choice if weight loss is a major goal and GLP-1 hasn’t been tried
JS is a 63-year-old male with type 2 diabetes, heart failure with reduced ejection fraction (HFrEF, EF 35%), and chronic kidney disease (eGFR 45 mL/min/1.73m²). His current medications include metformin, carvedilol, and lisinopril. His A1c is 7.4%. His cardiologist wants to add a medication to reduce hospitalizations for heart failure and slow CKD progression. Which of the following agents would be most appropriate?
A. Sitagliptin (Januvia)
B. Saxagliptin (Onglyza)
C. Dapagliflozin (Farxiga)
D. Glipizide
Answer: C. Dapagliflozin (Farxiga)
Rationale:
Farxiga is an SGLT2 inhibitor that provides:
Cardiovascular benefit (↓ HF hospitalizations & CV death in HFrEF)
Renal protection (slows CKD progression, even in non-diabetics)
A1c is already controlled — benefit here is CV and renal
Sitagliptin and saxagliptin offer no CV benefit, and saxagliptin may worsen HF
Glipizide increases hypoglycemia risk, with no CV or renal benefit
Match each of the following insulin products to its most appropriate approximate days’ supply when used as intended. Assume each pen contains the standard number of units (usually 300 units/pen unless specified otherwise) and average usage.
A. Novolin R vial
B. Afrezza (opened)
C. Humulin N pen
D. Toujeo (pen in use)
E. Apidra (pen in use)
1. 42 days
2. 28 days
3. 14 days
4. 56 days
5. 10 days
Answer Matching:
A → 1 (Novolin R vial = 42 days)
B → 5 (Afrezza = 10 days once opened)
C → 3 (Humulin N pen = 14 days)
D → 4 (Toujeo pen = 56 days)
E → 2 (Apidra pen = 28 days)
Rationale:
Each insulin has a specific beyond-use date once opened or at room temperature:
Novolin R (vial) = 42 days
Afrezza = 10 days
Humulin N pen = 14 days
Toujeo pen = 56 days
Apidra pen = 28 days
Match each insulin product with its correct onset of action classification.
A. Novolin R
B. Rezvoglar
C. Tresiba
D. Admelog
E. Fiasp
1. Short acting
2. Long acting
3. Ultra long acting
4. Rapid acting
5. Ultra rapid acting
Answer Matching:
A → 4 (NovoLin R = Short-acting)
B → 2 (Rezvoglar = Long-acting)
C → 3 (Tresiba = Ultra-long-acting)
D → 4 (Admelog = Rapid-acting)
E → 5 (Fiasp = Ultra-rapid-acting)
A patient brings in a glucose log with the following average blood glucose over the past 3 months:165 mg/dL
Using the formula: A1c (%) = (Average Glucose + 46.7) / 28.7
What is the patient's estimated A1c?
A. 6.8%
B. 7.2%
C. 7.4%
D. 7.6%
Calculation:A1c = (165 + 46.7) / 28.7A1c = 211.7 / 28.7 ≈ 7.4%
Which of the following diagnostic tests is typically used to help rule out other conditions and support a diagnosis of irritable bowel syndrome (IBS)?
A. Urine sample
B. Colonoscopy
C. Stool culture
D. Abdominal X-ray
✅ Correct Answer: B. Colonoscopy
Rationale:A colonoscopy is often used to rule out more serious gastrointestinal conditions (like IBD or colorectal cancer) when diagnosing IBS, especially in patients with red flag symptoms (e.g., weight loss, anemia, rectal bleeding). While IBS itself is a clinical diagnosis based on Rome IV criteria, colonoscopy is used to exclude other diseases.
A 49-year-old male is diagnosed with H. pylori-positive peptic ulcer disease. He has no history of penicillin allergy. Which of the following first-line regimens is most appropriate?
A. Omeprazole + Clarithromycin + Amoxicillin
B. Omeprazole + Clarithromycin + Metronidazole
C. Omeprazole + Tetracycline + Bismuth + Metronidazole
D. Ranitidine + Clarithromycin + Amoxicillin
✅ Correct Answer: C. Omeprazole + Tetracycline + Bismuth + Metronidazole
Rationale:According to updated ACG guidelines, bismuth quadruple therapy is now the preferred first-line regimen for H. pylori eradication in most patients, regardless of penicillin allergy status, due to increasing resistance to clarithromycin. It includes:
PPI (e.g., omeprazole)
Bismuth
Tetracycline
Metronidazole
A 64-year-old male is admitted to the ICU with septic shock and is currently intubated and on norepinephrine. He has a past medical history of GERD and atrial fibrillation. His labs today show platelet count 85,000/mm³ and INR 1.5. Which of the following medications would be most appropriate for stress ulcer prophylaxis? Select all that apply.
A. Famotidine (Pepcid)
B. Nizatidine (Axid)
C. Esomeprazole (Nexium)
D. Lansoprazole (Prevacid)
E. Pantoprazole (Protonix)
Answer: A, C, D, E (Famotidine, Nexium, Prevacid, Protonix)
Rationale:Stress ulcer prophylaxis (SUP) is indicated in critically ill patients with ≥1 major risk factor, including:
Mechanical ventilation >48 hrs
Coagulopathy (INR >1.5 or platelets <150k)
Sepsis
ICU admission >7 days
Traumatic brain/spinal cord injury
History of GI bleed
Appropriate agents for SUP include:
PPIs: Pantoprazole (Protonix), Esomeprazole (Nexium), Lansoprazole (Prevacid)
H2RAs: Famotidine (Pepcid), Nizatidine (Axid) – less preferred if renal dysfunction or thrombocytopenia
Choose based on route availability, renal function, drug interactions
Axid (nizatidine) is less commonly used and not preferred in thrombocytopenia.
A 71-year-old male presents to the ED with melena and lightheadedness. He has a past medical history of osteoarthritis and has been taking ibuprofen 800 mg TID for the past 3 months. Endoscopy confirms a bleeding gastric ulcer. What is the most appropriate initial management step?
A. Continue NSAID and add sucralfate
B. Switch NSAID to celecoxib
C. Discontinue NSAID and start omeprazole
D. Add famotidine to current NSAID regimen
E. Add misoprostol to prevent future ulcers
Answer: C. Discontinue NSAID and start omeprazole
Rationale:
In NSAID-induced ulcers, the first step is to stop the NSAID if possible
PPIs (e.g., omeprazole) promote healing and reduce recurrence risk
H2RAs and sucralfate are less effective for healing NSAID-induced ulcers
Celecoxib is a COX-2 selective NSAID and may be used later only if NSAIDs are necessary, but not in acute bleeding
Misoprostol can prevent NSAID ulcers but is not first-line for acute treatment
A 53-year-old male presents with epigastric pain and early satiety. He tests positive on a urea breath test for H. pylori. He has a documented penicillin allergy and took azithromycin for sinusitis 2 weeks ago. Which of the following is the most appropriate treatment regimen?
A. Omeprazole + Clarithromycin + Amoxicillin
B. Nexium + Clarithromycin + Metronidazole
C. Nexium + Bismuth + Tetracycline + Metronidazole
D. Famotidine + Clarithromycin + Amoxicillin
E. Nexium + Tetracycline + Amoxicillin
Answer: C. Nexium + Bismuth + Tetracycline + Metronidazole
Rationale:
Patient has a penicillin allergy → avoid amoxicillin
Recent macrolide (azithromycin) use = avoid clarithromycin due to resistance
This makes bismuth quadruple therapy ideal:
PPI (e.g., Nexium)
Bismuth subsalicylate
Tetracycline
Metronidazole
This regimen is effective even with macrolide resistance or beta-lactam allergy
Which of the following best describes the typical appearance of an NSAID-induced peptic ulcer?
A. Superficial and shallow
B. Deep and severe
C. Painless and flat
D. Raised and inflamed
Answer: B. Deep and severe
Rationale:
NSAID ulcers are classically deep and severe, often with more mucosal damage
This is due to inhibition of prostaglandin synthesis, which weakens the GI mucosal defense
In contrast, H. pylori ulcers are often superficial and may be more chronic but less acutely severe
Which of the following contribute to constipation? Select all that apply.
A. Verapamil
B. Amitriptyline
C. Low fiber intake
D. Metoclopramide
E. High water intake
Answer: A, B, C
Rationale:
Verapamil → non-dihydropyridine CCB → slows GI motility
Amitriptyline → TCA with anticholinergic effects → slows gut
Low fiber intake → decreases stool bulk, promotes constipation
Metoclopramide actually enhances GI motility
High water intake helps prevent constipation
Which of the following are appropriate strategies to help manage or support recovery from diarrhea? Select all that apply.
A. Frequent hand washing
B. Hydration with fluids and electrolytes
C. High-fat diet
D. BRAT diet (bananas, rice, applesauce, toast)
E. Avoiding fluids to let the gut "rest"
Answer: A, B, D
Rationale:
Hand washing prevents spread of infectious diarrhea
Hydration is critical to replace lost fluids/electrolytes
BRAT diet is bland, low-fiber, and easy on the stomach — good during recovery
High-fat foods and avoiding fluids are inappropriate and can worsen symptoms or prolong dehydration
A patient presents with new-onset loose stools. Upon review of their medication list, which of the following drugs could be contributing to their diarrhea symptoms? Select all that apply.
A. Levothyroxine
B. Metformin
C. St. John’s Wort
D. Lisinopril
E. Diphenhydramine
Answer: A, B, C
Rationale:
Levothyroxine: excess thyroid hormone → speeds up GI motility → diarrhea
Metformin: very common cause of GI upset and diarrhea, especially when starting or titrating
St. John’s Wort: may cause GI side effects including diarrhea
Lisinopril: can rarely cause GI symptoms, but not a common cause of diarrhea
Diphenhydramine: anticholinergic → more likely to cause constipation, not diarrhea
Match each type of diarrhea with its most appropriate underlying mechanism:
A. Osmotic
B. Altered Motility
C. Exudative
D. Secretory
1. Increased intestinal secretion and decreased water absorption
2. Poorly absorbed solutes remain in lumen and draw fluid into the intestine
3. Inflammation and infiltration of intestinal mucosa causing fluid and blood loss
4. Dysfunction of the enteric nervous system altering transit time and motility
Answer Key:
A → 2 (Osmotic)
B → 4 (Altered Motility)
C → 3 (Exudative)
D → 1 (Secretory)
Quick Rationale:
Osmotic: lactose intolerance, sorbitol → unabsorbed solutes
Secretory: cholera, VIPoma, bile acid diarrhea
Exudative: IBD, infections → blood, mucus, WBCs
Altered Motility: IBS, diabetic neuropathy
A 29-year-old male presents to the urgent care clinic with acute onset of watery, sometimes bloody diarrhea, abdominal cramping, and a low-grade fever after returning from a camping trip. Which of the following organisms are known causes of acute infectious diarrhea? Select all that apply.
A. Escherichia coli (E. coli)
B. Salmonella
C. Shigella
D. Clostridioides difficile
E. Helicobacter pylori
Answer: A, B, C, D
Rationale:
E. coli (especially EHEC): can cause watery or bloody diarrhea
Salmonella: often foodborne, acute diarrhea + fever
Shigella: highly contagious, causes bloody/mucoid stools
C. difficile: often nosocomial, especially after antibiotics — still an acute diarrheal illness
H. pylori: associated with gastritis/ulcers, not diarrhea
A 46-year-old female is scheduled for an elective laparoscopic cholecystectomy. She has a history of severe nausea with prior anesthesia. The surgical team wants to prevent postoperative nausea and vomiting (PONV). Which of the following medications are appropriate options for PONV prophylaxis? Select all that apply.
A. Aprepitant
B. Granisetron
C. Lorazepam
D. Metoclopramide
E. Diphenhydramine
Answer: A, B, D
Rationale:
Aprepitant: NK1 receptor antagonist → prevents PONV; often used in high-risk patients
Granisetron: 5-HT3 receptor antagonist (like ondansetron) → effective in PONV
Metoclopramide: dopamine antagonist → sometimes used adjunctively
Lorazepam: may help anticipatory nausea (e.g., chemo), not typically for PONV
Diphenhydramine: not first-line for PONV; more useful in motion sickness or vertigo
A 6-year-old child is brought to the clinic by her parent for nausea and vomiting since last night. She has had 2 episodes of vomiting but no diarrhea, fever, or abdominal tenderness. She is alert, tolerating small sips of juice, and says she’s hungry. Which of the following is the most appropriate management at this time?
A. Order abdominal ultrasound to rule out appendicitis
B. Prescribe omeprazole for suspected gastritis
C. Reassure parent and advise clear liquids only for 48 hours
D. Administer oral ondansetron and encourage hydration with fluids
Answer: D. Administer oral ondansetron and encourage hydration with fluids
Rationale:
In a clinically stable child with mild N/V and no red flags (e.g., pain, dehydration, blood), the best approach is:
Oral rehydration
Ondansetron (Zofran) to reduce vomiting and improve fluid tolerance
Imaging or meds like PPIs are not necessary without red flag symptoms
Clear liquids only for 48 hrs can cause nutritional deficiency and isn’t evidence-based — encourage regular diet as tolerated
Match each levothyroxine dose to its correct tablet color:
A. 25 mcg
B. 50 mcg
C. 88 mcg
D. 125 mcg
E. 137 mcg
1. Olive
2. White
3. Orange
4. Brown
5. Turquoise
Answer Key:
A → 3 (25 mcg = Orange)
B → 2 (50 mcg = White)
C → 1 (88 mcg = Olive)
D → 4 (125 mcg = Brown)
E → 5 (137 mcg = Turquoise)
Orangutans Will Vomit On You Right Before They Become Large, Proud Giants
A 15-year-old male with type 1 diabetes presents to the emergency department with abdominal pain, vomiting, and rapid breathing. Labs confirm diabetic ketoacidosis (DKA). A separate 65-year-old female with newly diagnosed type 2 diabetes presents with confusion and glucose of 920 mg/dL; she is diagnosed with hyperosmolar hyperglycemic state (HHS).
What is the primary difference between these two conditions in terms of insulin status, and how can it be assessed?
A. DKA is associated with relative insulin deficiency; HHS is absolute insulin deficiency
B. Both DKA and HHS involve total insulin resistance
C. DKA involves absolute insulin deficiency; HHS involves relative insulin deficiency
D. C-peptide testing is used to detect hypoglycemia, not insulin production
Answer: C. DKA involves absolute insulin deficiency; HHS involves relative insulin deficiency
Rationale:
DKA = absolute insulin deficiency, most common in type 1 diabetes → ketone production and acidosis
HHS = relative insulin deficiency, more common in type 2 diabetes → hyperglycemia without ketosis
C-peptide is released in equal amounts to endogenous insulin (not present in exogenous insulin)
Low or undetectable C-peptide = insulin deficiency (T1DM/DKA)
Normal/high C-peptide = insulin resistance or T2DM (HHS)
A 42-year-old female with a history of untreated hyperthyroidism is brought to the ER with fever (103.9°F), tachycardia (HR 140), confusion, and tremors. She was recently started on antibiotics for pneumonia. Labs confirm thyroid storm. Which of the following medications are appropriate components of her management? Select all that apply.
A. Propranolol (Inderal)
B. Saturated Solution of Potassium Iodide (SSKI)
C. Propylthiouracil (PTU)
D. Solu-Medrol (methylprednisolone)
E. Levothyroxine
Answer: A, B, C, D
Rationale:Thyroid storm is a life-threatening medical emergency. Treatment targets blocking hormone effects, synthesis, and release: MedicationRole
-Propranolol Controls HR & blocks peripheral T4 → T3 conversion
-PTUInhibits new thyroid hormone synthesis and blocks T4 → T3 conversion
-SSKI (Iodide)Prevents release of stored hormone (give at least 1 hr after PTU)
-Solu-Medrol Reduces peripheral conversion & treats adrenal insufficiency
-Levothyroxine🚫 Contraindicated — this is for hypothyroidism, not storm
A 63-year-old female presents with fatigue, cold intolerance, and no bowel movement in the past 4 days. She has a history of type 2 diabetes, hypertension, and GERD. Labs today show:
TSH: 18.2 mIU/L (elevated)
Free T4: 0.6 ng/dL (low)
A1c: 7.4%
She is not currently on any thyroid medication. Her provider wants to initiate thyroid hormone replacement. Which of the following is the most appropriate therapy to initiate?
A. Triostat (liothyronine) 25 mcg PO daily
B. Synthroid 88 mcg PO daily
C. Levoxyl 88 mcg PO daily
D. Armour Thyroid 1 grain PO daily
Answer: C. Levoxyl 88 mcg PO daily
If a patient:
Has hypothyroidism
Is struggling with constipation, IBS-C, or GI discomfort
OR has had issues tolerating Synthroid in the past→ Levoxyl is a solid first-line levothyroxine brand choice.
A 38-year-old male presents with diabetic ketoacidosis (DKA). Initial labs reveal:
Blood glucose: 488 mg/dL
Serum K⁺: 3.1 mEq/L
Serum bicarbonate: 11 mEq/L
pH: 7.18
The provider wants to start IV fluids and Novolog (insulin aspart) for treatment. What is the most appropriate next step in managing this patient’s potassium and insulin?
A. Begin IV insulin immediately and monitor potassium every 6 hours
B. Hold insulin and give potassium replacement until K⁺ >3.5 mEq/L
C. Start insulin at a reduced dose and recheck potassium in 24 hours
D. Administer sodium bicarbonate to correct pH before addressing potassium
Answer: B. Hold insulin and give potassium replacement until K⁺ >3.5 mEq/L
Rationale:
Insulin drives potassium into cells, which can worsen hypokalemia and cause life-threatening arrhythmias
In DKA/HHS, if K⁺ <3.3–3.5, you must hold insulin and replace potassium first
Once K⁺ is safely >3.5, insulin can be started
Monitoring K⁺ is typically every 2–4 hours in acute settings, not just every 6–24
Chronic hyperglycemia causes both microvascular and macrovascular damage.
True / False
Answer: ✅ True
Rationale:
Microvascular = eyes, kidneys, nerves
Macrovascular = heart, brain, peripheral arteries
Continuous subcutaneous insulin infusion (CSII) pumps are primarily used for patients with type 1 diabetes, but they can occasionally be used in type 2 diabetes patients.
True / False
Answer: ✅ True
Quick Rationale:
CSII (insulin pumps) are mainly used in type 1 diabetes to mimic physiologic insulin delivery
Can also be used in type 2 diabetes if the patient is insulin-dependent, has high insulin needs, or struggles with glycemic control despite injections
A 72-year-old male with type 2 diabetes is being followed closely by the diabetes clinic. He is currently taking metformin 1000 mg BID and repaglinide (Prandin) 0.5 mg TID before meals. His glucose log shows frequent postprandial glucose readings between 70–90 mg/dL, especially after lunch and dinner. His A1c has decreased from 8.2% to 6.7% over the past 3 months. He reports feeling lightheaded and shaky in the afternoons.
Which of the following is the most appropriate next step in therapy?
A. Increase repaglinide to 1 mg TID
B. Discontinue metformin
C. Discontinue repaglinide based on postprandial glycemic trends
D. Add basal insulin to improve overnight glycemic control
Answer: C. Discontinue repaglinide based on postprandial glycemic trends
Rationale:
Repaglinide stimulates short-acting insulin release → reduces post-meal blood sugar
If postprandial readings are consistently low, the med is likely too aggressive or no longer needed
Metformin is safe to continue
Adding insulin would worsen hypoglycemia
Increasing repaglinide would be inappropriate with lows already occurring
A 68-year-old male with a history of type 2 diabetes, heart failure with reduced ejection fraction (EF 35%), and chronic kidney disease stage 3a (eGFR 48 mL/min/1.73m²) presents for follow-up. His current medications include metformin 1000 mg BID, lisinopril 20 mg daily, and carvedilol 25 mg BID. His A1c is 7.6%. The provider wants to add a medication that will provide both cardiovascular and renal protection.
Which of the following is the most appropriate choice?
A. Glipizide
B. Empagliflozin
C. Sitagliptin
D. Pioglitazone
✅ Correct Answer: B. Empagliflozin
Rationale:
Empagliflozin is an SGLT2 inhibitor with strong evidence for cardiovascular and renal protection, especially in patients with HFrEF and CKD, regardless of A1c level.
It reduces hospitalization for heart failure, slows CKD progression, and is beneficial even in eGFR down to 20–25 mL/min in certain cases.
Other options:
A. Glipizide: No CV or renal benefits; increased risk of hypoglycemia.
C. Sitagliptin: Neutral on CV and renal outcomes.
D. Pioglitazone: May worsen heart failure due to fluid retention.
A 35-year-old female presents for her annual wellness visit. She has a BMI of 31 kg/m² and a history of polycystic ovary syndrome (PCOS). She also has a remote history of gestational diabetes with her first pregnancy and is currently on antiretroviral therapy for HIV. Her most recent labs show no symptoms of hyperglycemia.
Based on ADA guidelines, should this patient be screened for diabetes at this visit?
A. No, she is under age 40 and asymptomatic
B. No, only patients with a family history of diabetes require screening
C. Yes, due to her BMI and history of PCOS
D. Yes, but only if she has microalbuminuria
Answer: ✅ C. Yes, due to her BMI and history of PCOS
Rationale:
ADA recommends diabetes screening in adults of any age who are overweight or obese (BMI ≥25 or ≥23 in Asians) plus one or more risk factors, including:
PCOS
History of gestational diabetes (GDM)
HIV infection
Physical inactivity, family history, high-risk race/ethnicity
So this patient meets multiple criteria for early screening even though she's under 40
Which of the following best describes the primary pathophysiologic abnormality in type 2 diabetes mellitus (T2DM)?
A. Absolute insulin deficiency due to autoimmune beta-cell destruction
B. Decreased insulin sensitivity in peripheral tissues, often with relative insulin deficiency
C. Autoantibody production leading to loss of pancreatic alpha cells
D. Increased insulin sensitivity and increased hepatic glucose uptake
Answer: ✅ B. Decreased insulin sensitivity in peripheral tissues, often with relative insulin deficiency
Rationale:
T2DM is primarily caused by:
Insulin resistance in muscle, fat, and liver
Followed by progressive beta-cell dysfunction → relative insulin deficiency
T1DM is autoimmune with absolute insulin deficiency (choice A)
There is no increase in insulin sensitivity or hepatic glucose uptake in T2DM (choice D)
Alpha cells aren’t primarily involved in diabetes pathogenesis (choice C)
Nausea:
A subjective sensation of the urge to vomit, often accompanied by autonomic symptoms such as salivation, sweating, and pallor.
Vomiting:
The forceful expulsion of gastric contents through the mouth, coordinated by the vomiting center in the brainstem.
Which of the following medications would most likely be used to treat irritable bowel syndrome with diarrhea (IBS-D)?
A. Lubiprostone
B. Linaclotide
C. Rifaximin
D. Lactulose
Answer: ✅ C. Rifaximin
Rationale:
Rifaximin is a non-absorbable antibiotic approved for IBS-D
Lubiprostone and linaclotide are used for IBS-C (constipation)
Lactulose is used for constipation and hepatic encephalopathy, not IBS-D
A 29-year-old patient presents to the pharmacy with complaints of diarrhea for the past day. She denies fever, nausea, vomiting, or blood in the stool. She feels fine otherwise and is able to drink fluids. What is the most appropriate first-line treatment?
A. Bismuth subsalicylate
B. Loperamide
C. Ciprofloxacin
D. Ondansetron
Answer: ✅ B. Loperamide
Rationale:
Loperamide is first-line for uncomplicated, non-infectious diarrhea
No red flags (fever, blood, systemic illness) = safe to use
Bismuth is helpful, but loperamide is preferred for quick symptom relief
Ciprofloxacin not needed unless bacterial infection suspected
Ondansetron treats nausea, not diarrhea
AM is a 34-year-old female who presents to the clinic with a 6-month history of frequent loose stools, bloating, and abdominal cramping. She reports 4–5 loose bowel movements per day that are worse after eating. She denies fever, weight loss, blood in stool, or recent travel. A full GI workup is negative for infection, IBD, or celiac disease. She is diagnosed with irritable bowel syndrome with diarrhea predominance (IBS-D).
Which of the following is the most appropriate initial management strategy for her symptoms?
A. Start rifaximin 550 mg TID for 14 days
B. Recommend a low FODMAP diet
C. Initiate loperamide 2 mg before each meal daily
D. Prescribe linaclotide 290 mcg daily
Answer: ✅ B. Recommend a low FODMAP diet
Rationale:
First-line management of IBS-D = dietary modifications, especially low FODMAP
Rifaximin and loperamide may be added later if diet fails
Linaclotide is used for IBS-C, not IBS-D
A 45-year-old woman returns to the pharmacy concerned that her tongue has turned black and discolored, but she has no pain, swelling, or other symptoms. She recently started a new medication to help manage diarrhea during a trip abroad.
Which of the following medications is most likely causing this side effect?
A. Metronidazole
B. Loperamide
C. Bismuth subsalicylate
D. Diphenoxylate/atropine
Answer: ✅ C. Bismuth subsalicylate
Rationale:
Bismuth reacts with sulfur in saliva to form bismuth sulfide, a harmless black compound that can coat the tongue and stool
Black hairy tongue is a known, benign side effect
The other agents listed do not cause this discoloration
A patient with osteoarthritis and a history of gastric ulcers is prescribed Vimovo to manage her joint pain. She asks which medications are included in this pill. Vimovo is a combination of which of the following?
A. Ibuprofen and lansoprazole
B. Naproxen and esomeprazole
C. Celecoxib and omeprazole
D. Indomethacin and pantoprazole
Answer: ✅ B. Naproxen and esomeprazole
An 84-year-old female resident in a long-term care facility has not had a bowel movement in 3 days. She is mostly bedbound, eats a soft diet, and takes multiple medications including opioids. She is alert but reports abdominal discomfort and bloating. What is the most appropriate initial treatment?
A. Senna
B. Lactulose
C. Loperamide
D. Bismuth subsalicylate
Answer: ✅ B. Lactulose
Rationale:
Lactulose is a gentle osmotic laxative commonly used for elderly, constipated, bedbound patients
It draws water into the colon, softening stool and stimulating motility
Senna is a stimulant laxative and can be irritating — often added after osmotics fail
Loperamide is for diarrhea — avoid in constipation
Bismuth treats diarrhea, not constipation
A 48-year-old male comes to the pharmacy complaining of nausea, vomiting, and noticing blood in his stool this morning. He has no known chronic conditions but appears pale and fatigued. He asks if there is an OTC product he can take to help.
What is the most appropriate recommendation?
A. Recommend loperamide and monitor symptoms for 24 hours
B. Recommend bismuth subsalicylate and bland diet
C. Refer the patient to their primary care provider immediately
D. Recommend famotidine for possible gastritis
Answer: ✅ C. Refer the patient to their primary care provider immediately
Rationale:
Blood in the stool, especially with nausea/vomiting, can indicate serious GI pathology (e.g., upper or lower GI bleed, infection, or inflammatory bowel disease)
These are red flag symptoms — not appropriate for self-care
OTC meds could delay proper diagnosis and treatment
Which of the following best describes the chemoreceptor trigger zone (CTZ) and its role in vomiting?
A. It is located in the liver and detects toxins in the bloodstream
B. It is a brainstem region that triggers vomiting in response to chemical stimuli
C. It is a part of the cerebellum that regulates gastric motility
D. It is located in the spinal cord and controls vomiting via sympathetic input
Answer: ✅ B. It is a brainstem region that triggers vomiting in response to chemical stimuli
Rationale:
The CTZ is located in the medulla (area postrema) and lies outside the blood-brain barrier, allowing it to detect circulating toxins, drugs, or metabolic imbalances
It sends signals to the vomiting center in the brain to initiate nausea/vomiting
Receptors involved include dopamine (D2), serotonin (5-HT3), histamine (H1), muscarinic, and NK1
A 42-year-old woman is going on a cruise and asks about preventing motion sickness. She has a history of nausea and dizziness while traveling. Her provider recommends Transderm Scōp (scopolamine).
Which of the following statements is correct regarding this medication?
A. It is a dopamine antagonist taken orally every 6 hours
B. It is a 5-HT3 antagonist applied as a patch every 12 hours
C. It is an anticholinergic patch applied behind the ear every 72 hours
D. It is an antihistamine nasal spray used only after symptoms begin
Answer: ✅ C. It is an anticholinergic patch applied behind the ear every 72 hours
Rationale:
Scopolamine (Transderm Scōp) is a muscarinic (anticholinergic) used for motion sickness
It is applied behind the ear at least 4 hours before travel and replaced every 72 hours if needed
Side effects include dry mouth, drowsiness, blurred vision, and anticholinergic effects
A 29-year-old woman who is 7 weeks pregnant presents with persistent nausea and vomiting. She is able to tolerate small amounts of fluids and has no signs of dehydration. She has tried dietary changes and ginger without relief. What is the recommended first-line pharmacologic treatment for nausea and vomiting in pregnancy?
A. Ondansetron
B. Promethazine
C. Diclegis (doxylamine/pyridoxine)
D. Metoclopramide
Answer: ✅ C. Diclegis (doxylamine/pyridoxine)
Rationale:
According to ACOG guidelines, the first-line pharmacologic treatment for nausea and vomiting in pregnancy is a combination of:
Doxylamine (antihistamine)
Pyridoxine (vitamin B6)
Available OTC (separately) or Rx as Diclegis
Ondansetron, promethazine, and metoclopramide may be used second-line or for more severe symptoms